Package | Dosage | Price | Price per Dose | |
---|---|---|---|---|
Dosage: 3mg | ||||
90 tab | 3mg | €1,436.14 | €15.96 | |
60 tab | 3mg | €983.30 | €16.39 | |
30 tab | 3mg | €517.52 | €17.25 | |
20 tab | 3mg | €353.64 | €17.68 | |
10 tab | 3mg | €181.13 | €18.11 | |
Dosage: 7mg | ||||
90 tab | 7mg | €1,669.03 | €18.54 | |
60 tab | 7mg | €1,138.56 | €18.98 | |
30 tab | 7mg | €595.15 | €19.84 | |
20 tab | 7mg | €405.39 | €20.27 | |
10 tab | 7mg | €207.00 | €20.70 | |
Dosage: 14mg | ||||
90 tab | 14mg | €1,824.28 | €20.27 | |
60 tab | 14mg | €1,242.06 | €20.70 | |
30 tab | 14mg | €646.90 | €21.56 | |
20 tab | 14mg | €439.89 | €22.00 | |
10 tab | 14mg | €224.25 | €22.43 |
Semaglutide Description
Overview of Semaglutide
Semaglutide is a medication that belongs to a class of drugs called GLP-1 receptor agonists. It is primarily used to help manage type 2 diabetes, offering a way to control blood sugar levels effectively. In addition to its glucose-lowering properties, Semaglutide has gained attention for its potential to promote weight loss, making it a versatile option for individuals struggling with obesity along with diabetes. This medication has been developed to mimic the actions of a natural hormone involved in appetite regulation and insulin secretion, providing a comprehensive approach to metabolic health.
How Semaglutide Works
Semaglutide works by stimulating specific receptors in the brain and pancreas. It enhances insulin secretion when blood sugar levels are high and suppresses the release of glucagon, a hormone that raises blood glucose. Its action slows down gastric emptying, leading to a feeling of fullness for longer periods after eating. These combined effects help in reducing post-meal blood sugar spikes and decrease overall calorie intake. Due to these mechanisms, Semaglutide not only helps control blood sugar but also assists in weight management, which is often a challenge in type 2 diabetes.
Effectiveness and Benefits
Many users report significant improvements in blood sugar control after starting Semaglutide. Clinical trials have demonstrated its effectiveness in reducing HbA1c levels, a key marker for long-term glucose management. Beyond glycemic control, patients often experience notable weight loss, which can be beneficial for overall health and cardiovascular risk reduction. The medication's once-weekly injection schedule increases convenience and adherence, making it a favored choice among patients and healthcare providers alike. Its dual benefits of lowering blood sugar and supporting weight loss contribute to better disease management and potentially reduce complications associated with diabetes.
Potential Side Effects and Risks
Like many medications, Semaglutide comes with potential side effects. Most users experience gastrointestinal symptoms such as nausea, vomiting, diarrhea, or constipation, especially at the beginning of treatment. These effects tend to diminish over time as the body adjusts. Some individuals might experience decreased appetite, which contributes to weight loss, but in rare cases, more serious issues like pancreatitis or changes in kidney function may occur. It is important for users to consult with a healthcare provider before starting Semaglutide to ensure it is appropriate for their health condition and to monitor for any adverse reactions during treatment.
Usage and Precautions
Semaglutide is administered via subcutaneous injection, usually once a week. Proper technique and dosage instructions provided by a healthcare professional are essential for safe and effective use. Patients should inform their doctor about any existing medical conditions, especially pancreatic issues or kidney problems. Regular monitoring of blood sugar, kidney function, and overall health is recommended during treatment. Pregnant or breastfeeding women should discuss the risks and benefits with their healthcare provider, as safety data in these groups are limited. As part of a comprehensive treatment plan, Semaglutide should be combined with a balanced diet and regular exercise for optimal results.